This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brugman, S. Articles by Seeley, R. J. Search for Related Content PubMed PubMed Citation Articles by Brugman, S. Articles by Seeley, R. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB NALTREXONE

Combined Blockade of Both µ- and -Opioid Receptors Prevents the Acute Orexigenic Action of Agouti-Related Protein

Department of Animal Physiology (S.B.), University of Groningen, 9750 AA, Haren, Groningen, The Netherlands; and Department of Psychiatry (D.J.C., S.C.W., R.J.S.), University of Cincinnati, Cincinnati, Ohio 45267

Address all correspondence and requests for reprints to: Randy J. Seeley, Ph.D., Department of Psychiatry, University of Cincinnati, Cincinnati, Ohio 45267-0559. E-mail: randy.seeley{at}uc.edu.

Agouti-related protein (AgRP) is an endogenous antagonist at the melanocortin 3 and 4 receptor in the hypothalamus. Central administration of AgRP produces a robust increase in food intake, and this effect can be blocked by administration of nonspecific opioid receptor antagonist. Such results implicate opioid receptors as critical to mediating the effects of AgRP. To determine which opioid receptor subtype is critical, we first determined the highest i3vt (administered into the third ventricle) dose of two specific opioid antagonists, nor-Binaltorphine or ß-funaltrexamine, that did not influence food intake on their own. Then, rats were pretreated with either of these two antagonists before i3vt AgRP and access to a high-fat diet. For neither the - nor the µ-specific antagonist was there any effect to block the effects of AgRP on food intake. However, administration of both the - and µ-receptor antagonists does significantly reduce the effect of AgRP. The current results implicate opioid receptors as critical downstream mediators of the potent effects of AgRP to increase food intake but indicate that either µ- or -receptor activation is sufficient for AgRP’s effect.

This article has been cited by other articles:

				F. Y. Obese, B. K. Whitlock, B. P. Steele, F. C. Buonomo, and J. L. Sartin Long-term feed intake regulation in sheep is mediated by opioid receptors J Anim Sci, January 1, 2007; 85(1): 111 - 117. [Abstract] [Full Text] [PDF]

				V. S. Densmore, N. M. Morton, J. J. Mullins, and J. R. Seckl 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Induction in the Arcuate Nucleus by High-Fat Feeding: A Novel Constraint to Hyperphagia? Endocrinology, September 1, 2006; 147(9): 4486 - 4495. [Abstract] [Full Text] [PDF]

				A. Tabarin, Y. Diz-Chaves, M. d. C. Carmona, B. Catargi, E. P. Zorrilla, A. J. Roberts, D. V. Coscina, S. Rousset, A. Redonnet, G. C. Parker, et al. Resistance to Diet-Induced Obesity in {micro}-Opioid Receptor-Deficient Mice: Evidence for a "Thrifty Gene" Diabetes, December 1, 2005; 54(12): 3510 - 3516. [Abstract] [Full Text] [PDF]

				N. R. Vulliemoz, E. Xiao, L. Xia-Zhang, S. L. Wardlaw, and M. Ferin Central Infusion of Agouti-Related Peptide Suppresses Pulsatile Luteinizing Hormone Release in the Ovariectomized Rhesus Monkey Endocrinology, February 1, 2005; 146(2): 784 - 789. [Abstract] [Full Text] [PDF]